Concepedia

Kimberly Noonan

KN

Statistics

Publications

13

Citations

788

H-Index

12

Active since

1993

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Colorado Blood Cancer Institute

Massachusetts General Hospital

U-M Rogel Cancer Center

Kimberly Noonan is an author at Dana-Farber Cancer Institute specializing in pharmacotherapy, medicine, and oncology.

Publications per year

1993–2020

13

Publications

13

Antiemetics: ASCO Guideline Update

Paul J. Hesketh, Mark G. Kris, Ethan Basch et al. · Journal of Clinical Oncology · 2020 · 457 citations

Pharmacy, Oncology, Pharmacotherapy +17

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

Irene M. Ghobrial, Chia‐Jen Liu, Oksana Zavidij et al. · American Journal of Hematology · 2019 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

NCCN antiemesis practice guidelines.

David S. Ettinger, Steven Huber, Mark G. Kris et al. · PubMed · 1997 · 48 citations

Pharmacy, Pharmacotherapy, Chemotherapy +7

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Irene M. Ghobrial, Ashraf Badros, James J. Vredenburgh et al. · Blood · 2016 · 34 citations

Medicine, Oncology, Pharmacotherapy +13

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

Irene M. Ghobrial, Robert Redd, Philippe Armand et al. · Leukemia · 2015 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +12

1–5 of 13